The Obesity Action Coalition (OAC) is urging Starbucks to change course on a reported plan to discontinue health plan coverage of GLP-1 medications for obesity. Health advocates fear that withdrawing coverage of these prescriptions could affect essential care for individuals living with obesity.

A growing number of individuals taking GLP-1 medications have reported an unusual bad-breath issue known as “Ozempic Breath.” This article explores how the side effect might arise and why health experts believe it warrants attention.